Polaryx Therapeutics, today announced that it has received from the U.S. Food and Drug Administration (FDA) both Rare Pediatric Disease and Orphan Drug Designations ... Dec 18
Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan® (rituximab)... Dec 18
rBIO, an early-stage synthetic biology company focused on reducing the cost of prescription drugs, has announced its first in-lab milestone: synthetic production of ... Dec 17
-Advertisements-